Interferon Beta-1b-Induced Sweet'S Syndrome In A Patient With Multiple Sclerosis

International Journal of DermatologyVolume 54, Issue 4 p. 456-458 Case Report Interferon beta-1b-induced Sweet's syndrome in a patient with multiple sclerosis Young Jin Kim MD, Young Jin Kim MD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South KoreaSearch for more papers by this authorHye Young Lee MD, Corresponding Author Hye Young Lee MD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South Korea Correspondence Dr Ji Yeoun Lee, md, phd Department of Dermatology School of Medicine and Medical Research Institute Chungbuk National University 52 Naesoodong-ro Heungdeok-gu Cheongju Chungbuk 361-763 South Korea E-mail: [email protected]Search for more papers by this authorJi Yeoun Lee MD, PhD, Ji Yeoun Lee MD, PhD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South KoreaSearch for more papers by this authorTae Young Yoon MD, PhD, Tae Young Yoon MD, PhD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South KoreaSearch for more papers by this author Young Jin Kim MD, Young Jin Kim MD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South KoreaSearch for more papers by this authorHye Young Lee MD, Corresponding Author Hye Young Lee MD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South Korea Correspondence Dr Ji Yeoun Lee, md, phd Department of Dermatology School of Medicine and Medical Research Institute Chungbuk National University 52 Naesoodong-ro Heungdeok-gu Cheongju Chungbuk 361-763 South Korea E-mail: [email protected]Search for more papers by this authorJi Yeoun Lee MD, PhD, Ji Yeoun Lee MD, PhD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South KoreaSearch for more papers by this authorTae Young Yoon MD, PhD, Tae Young Yoon MD, PhD Department of Dermatology, School of Medicine and Medical Research Institute, Chungbuk National University, Cheongju, South KoreaSearch for more papers by this author First published: 20 June 2013 https://doi.org/10.1111/j.1365-4632.2012.05840.xCitations: 5Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Fett DL, Gibson LE, Su WP. Sweet's syndrome: systemic signs and symptoms and associated disorders. Mayo Clin Proc 1995; 70: 234– 240. 2 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655– 661. 3Webster GF, Knobler RL, Lublin FD, et al. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol 1996; 34(2 Pt 2): 365– 367. 4Tai YJ, Tam M. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol 2005; 46: 154– 157. 5Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol 1998; 39: 1024– 1028. 6Linden D. Severe Raynaud's phenomenon associated with interferon-beta treatment for multiple sclerosis. Lancet 1998; 352: 878– 879. 7Nousari HC, Kimyai-Asadi A, Tausk FA. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998; 352: 1825– 1826. 8Somani AK, Swick AR, McCormick TSCooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol 2008; 144: 1341– 1349. 9Sweet RD. An acute febrile neutrophilic dermatosis. Br J Dermatol 1964; 76: 349– 356. 10Walker DC, Cohen P. Trimethoprim-sulfamethoxazole-associated acute febrile neutrophilic dermatosis: case report and review of drug-induced Sweet's syndrome. J Am Acad Dermatol 1996; 34(5, pt2): 918– 923. 11Giasuddin AS, El-Orfi AH, Ziu MM, El-Barnawi NY. Sweet's syndrome: is the pathogenesis mediated by helper T cell type 1 cytokines? J Am Acad Dermatol 1998; 39: 940– 943. 12Brodkin RH, Schwartz RA. Sweet's syndrome with myelofibrosis and leukemia: partial response to interferon. Dermatology 1995; 190: 160– 163. 13Bianchi L, Masi M, Hagman JH, et al. Systemic interferon-alpha treatment for idiopathic Sweet's syndrome. Clin Exp Dermatol 1999; 24: 443– 445. 14Gheorghe L, Cotruta B, Trifu V, et al. Drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy. Int J Dermatol 2008; 47: 957– 959. Citing Literature Volume54, Issue4April 2015Pages 456-458 ReferencesRelatedInformation